Exchange: NASDAQ·Updated 07:59 PM EDT
News
all
press releases
PacBio Q2 Earnings Meet Estimates, Revenues Miss, 2026 Sales View Cut
PACB cuts its 2026 revenue outlook after Q2 sales fall 2%, as consumables and EMEA growth fail to offset weaker instruments and Asia-Pacific.
Zacks
More News
Pacific Biosciences of California (PACB) Reports Q2 Loss, Lags Revenue Estimates
Pacific Biosciences (PACB) delivered earnings and revenue surprises of 0.00% and -4.16%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
What's in Store for These 4 Healthcare Companies This Earnings Season?
McKesson, Cencora, Solventum and PacBio head into earnings with resilient demand offset by tariffs, funding pressure and pricing challenges.
Zacks
Beta Bionics, Inc. (BBNX) Reports Q2 Loss, Tops Revenue Estimates
Beta Bionics, Inc. (BBNX) delivered earnings and revenue surprises of +14.52% and +2.07%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Pacific Biosciences of California (PACB) Laps the Stock Market: Here's Why
Pacific Biosciences of California (PACB) reached $1.39 at the closing of the latest trading day, reflecting a +2.21% change compared to its last close.
Zacks
Here's Why Pacific Biosciences of California (PACB) Fell More Than Broader Market
In the most recent trading session, Pacific Biosciences of California (PACB) closed at $1.36, indicating a -5.56% shift from the previous trading day.
Zacks
Pacific Biosciences of California (PACB) Dips More Than Broader Market: What You Should Know
Pacific Biosciences of California (PACB) concluded the recent trading session at $1.49, signifying a -4.49% move from its prior day's close.
Zacks
Resmed Divests MatrixCare Business to Sharpen Focus on Connected Care
RMD's MatrixCare sale sharpens its focus on sleep, breathing and connected care while freeing resources for AI-powered digital health.
Zacks
NTRA's Signatera Gains EU IVDR Certification for Multiple Cancers
Natera's Signatera became the first personalized MRD test for solid tumors to earn EU IVDR certification, supporting broader expansion across Europe.
Zacks
Here's Why You Should Add Merit Medical Stock to Your Portfolio Now
MMSI's portfolio, acquisitions, R&D strategy and WRAPSODY upside support growth, though tariffs, China pressure and OEM headwinds persist.
Zacks

Advertisement|Remove ads.